Katharina Elisabeth Blankart : Citation Profile


Are you Katharina Elisabeth Blankart?

Universität Duisburg-Essen (95% share)
Universität Hamburg (5% share)

3

H index

0

i10 index

16

Citations

RESEARCH PRODUCTION:

9

Articles

RESEARCH ACTIVITY:

   7 years (2011 - 2018). See details.
   Cites by year: 2
   Journals where Katharina Elisabeth Blankart has often published
   Relations with other researchers
   Recent citing documents: 10.    Total self citations: 6 (27.27 %)

MORE DETAILS IN:
ABOUT THIS REPORT:

   Permalink: http://citec.repec.org/pfi221
   Updated: 2020-01-18    RAS profile: 2019-04-28    
   Missing citations? Add them    Incorrect content? Let us know

Relations with other researchers


Works with:

Stargardt, Tom (3)

Leidl, Reiner (2)

Authors registered in RePEc who have co-authored more than one work in the last five years with Katharina Elisabeth Blankart.

Is cited by:

Gu, Yuanyuan (2)

Lancsar, Emily (2)

Fernandez, Jose Luis (1)

Leidl, Reiner (1)

Hu, Min (1)

Cites to:

Devlin, Nancy (10)

Stargardt, Tom (8)

Schreyögg, Jonas (6)

Parkin, David (6)

Leidl, Reiner (5)

Anell, Anders (3)

Costa-i-Font, Joan (3)

Fernandez, Jose Luis (2)

Vandoros, Sotiris (2)

Claxton, Karl (2)

Docteur, Elizabeth (2)

Main data


Where Katharina Elisabeth Blankart has published?


Journals with more than one article published# docs
Health Policy6
The European Journal of Health Economics3

Recent works citing Katharina Elisabeth Blankart (2018 and 2017)


YearTitle of citing document
2017The bare necessities? A realist review of necessity argumentations used in health care coverage decisions. (2017). Kleinhout-Vliek, Tineke ; Boer, Bert ; de Bont, Antoinette . In: Health Policy. RePEc:eee:hepoli:v:121:y:2017:i:7:p:731-744.

Full description at Econpapers || Download paper

2018Confirmatory versus explorative endpoint analysis: Decision-making on the basis of evidence available from market authorization and early benefit assessment for oncology drugs. (2018). Niehaus, Ines ; Dintsios, Charalabos-Markos. In: Health Policy. RePEc:eee:hepoli:v:122:y:2018:i:6:p:599-606.

Full description at Econpapers || Download paper

2019Value assessment of disease-modifying therapies for Relapsing-Remitting Multiple Sclerosis: HTA evidence from seven OECD countries. (2019). Kanavos, Panos ; Tinelli, Michela ; Visintin, Erica. In: Health Policy. RePEc:eee:hepoli:v:123:y:2019:i:2:p:118-129.

Full description at Econpapers || Download paper

2019What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries. (2019). Cairns, John ; Maynou, Laia. In: Health Policy. RePEc:eee:hepoli:v:123:y:2019:i:2:p:130-139.

Full description at Econpapers || Download paper

2019Threats to the value of Health Technology Assessment: Qualitative evidence from Canada and Poland. (2019). Sevgur, Serperi ; Gambold, Liesl ; Zieliska, Dorota Anna ; Wranik, Wiesawa Dominika. In: Health Policy. RePEc:eee:hepoli:v:123:y:2019:i:2:p:191-202.

Full description at Econpapers || Download paper

2018What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries. (2018). Cairns, John ; Maynou, Laia. In: LSE Research Online Documents on Economics. RePEc:ehl:lserod:90877.

Full description at Econpapers || Download paper

2018Sacubitril/Valsartan (LCZ696): A Novel Treatment for Heart Failure and its Estimated Cost Effectiveness, Budget Impact, and Disease Burden Reduction in Germany. (2018). Gandjour, Afschin ; Ostwald, Dennis A. In: PharmacoEconomics. RePEc:spr:pharme:v:36:y:2018:i:10:d:10.1007_s40273-018-0688-4.

Full description at Econpapers || Download paper

2018Revealed and Stated Preferences of Decision Makers for Priority Setting in Health Technology Assessment: A Systematic Review. (2018). Lancsar, Emily ; Gu, Yuanyuan ; Zavarsek, Silva ; Ghijben, Peter . In: PharmacoEconomics. RePEc:spr:pharme:v:36:y:2018:i:3:d:10.1007_s40273-017-0586-1.

Full description at Econpapers || Download paper

2018The Relative Importance of Clinical, Economic, Patient Values and Feasibility Criteria in Cancer Drug Reimbursement in Canada: A Revealed Preferences Analysis of Recommendations of the Pan-Canadian On. (2018). Skedgel, Chris ; Hu, Min ; Wranik, Dominika. In: PharmacoEconomics. RePEc:spr:pharme:v:36:y:2018:i:4:d:10.1007_s40273-018-0610-0.

Full description at Econpapers || Download paper

2018New Medicines in Wales: The All Wales Medicines Strategy Group (AWMSG) Appraisal Process and Outcomes. (2018). Varnava, Alice ; Routledge, Philip A ; Hughes, Dyfrig A ; Samuels, Karen ; Bracchi, Robert. In: PharmacoEconomics. RePEc:spr:pharme:v:36:y:2018:i:5:d:10.1007_s40273-018-0632-7.

Full description at Econpapers || Download paper

Works by Katharina Elisabeth Blankart:


YearTitleTypeCited
2011A structured tool to analyse coverage decisions: Development and feasibility test in the field of cancer screening and prevention In: Health Policy.
[Full Text][Citation analysis]
article0
2012A systematic review of coverage decision-making on health technologies—Evidence from the real world In: Health Policy.
[Full Text][Citation analysis]
article6
2013Transparency vs. closed-door policy: Do process characteristics have an impact on the outcomes of coverage decisions? A statistical analysis In: Health Policy.
[Full Text][Citation analysis]
article3
2016Health benefit assessment of pharmaceuticals: An international comparison of decisions from Germany, England, Scotland and Australia In: Health Policy.
[Full Text][Citation analysis]
article5
2016Drug safety and the impact of drug warnings: An interrupted time series analysis of diabetes drug prescriptions in Germany and Denmark In: Health Policy.
[Full Text][Citation analysis]
article0
2016Dispensing behaviour of pharmacies in prescription drug markets In: Health Policy.
[Full Text][Citation analysis]
article0
2014Analysing coverage decision-making: opening Pandora’s box? In: The European Journal of Health Economics.
[Full Text][Citation analysis]
article1
2016The diffusion of generics after patent expiry in Germany In: The European Journal of Health Economics.
[Full Text][Citation analysis]
article1
2018The impact of physician-level drug budgets on prescribing behavior In: The European Journal of Health Economics.
[Full Text][Citation analysis]
article0

CitEc is a RePEc service, providing citation data for Economics since 2001. Sponsored by INOMICS. Last updated January, 6 2020. Contact: CitEc Team